IRIS Accounts Production v22.2.0.402 12361382 director 1.7.21 30.6.22 30.6.22 12/9/22 false true false false true false Auditors Opinion Ordinary share 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure123613822021-06-30123613822022-06-30123613822021-07-012022-06-30123613822020-06-30123613822020-07-012021-06-30123613822021-06-3012361382ns16:EnglandWales2021-07-012022-06-3012361382ns15:PoundSterling2021-07-012022-06-3012361382ns11:Director12021-07-012022-06-3012361382ns11:PrivateLimitedCompanyLtd2021-07-012022-06-3012361382ns11:SmallEntities2021-07-012022-06-3012361382ns11:Audited2021-07-012022-06-3012361382ns11:SmallCompaniesRegimeForDirectorsReport2021-07-012022-06-3012361382ns11:SmallCompaniesRegimeForAccounts2021-07-012022-06-3012361382ns11:FullAccounts2021-07-012022-06-3012361382ns11:OrdinaryShareClass12021-07-012022-06-3012361382ns11:CompanySecretary12021-07-012022-06-3012361382ns11:RegisteredOffice2021-07-012022-06-3012361382ns6:CurrentFinancialInstruments2022-06-3012361382ns6:CurrentFinancialInstruments2021-06-3012361382ns6:Non-currentFinancialInstruments2022-06-3012361382ns6:Non-currentFinancialInstruments2021-06-3012361382ns6:ShareCapital2022-06-3012361382ns6:ShareCapital2021-06-3012361382ns6:RetainedEarningsAccumulatedLosses2022-06-3012361382ns6:RetainedEarningsAccumulatedLosses2021-06-3012361382ns6:PlantMachinery2021-07-012022-06-3012361382ns6:PlantMachinery2021-06-3012361382ns6:PlantMachinery2022-06-3012361382ns6:PlantMachinery2021-06-3012361382ns6:WithinOneYearns6:CurrentFinancialInstruments2022-06-3012361382ns6:WithinOneYearns6:CurrentFinancialInstruments2021-06-3012361382ns11:OrdinaryShareClass12022-06-30
REGISTERED NUMBER: 12361382 (England and Wales)


















AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2022

FOR

INVEX THERAPEUTICS LTD

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3 to 5


INVEX THERAPEUTICS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 30 JUNE 2022







DIRECTOR: Dr J A Loveridge



SECRETARY: Oakwood Corporate Secretary Limited



REGISTERED OFFICE: 3rd Floor
1 Ashley Road
Altrincham
Cheshire
WA14 2DT



REGISTERED NUMBER: 12361382 (England and Wales)



SENIOR STATUTORY AUDITOR: Benjamin Furness



AUDITORS: Allens Accountants Limited
Registered Auditors and
Chartered Accountants
123 Wellington Road South
Stockport
Cheshire
SK1 3TH

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

BALANCE SHEET
30 JUNE 2022

30/6/22 30/6/21
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 2,805 1,444

CURRENT ASSETS
Debtors 5 314,751 110,027
Cash at bank 91,018 27,055
405,769 137,082
CREDITORS
Amounts falling due within one year 6 204,867 1,735
NET CURRENT ASSETS 200,902 135,347
TOTAL ASSETS LESS CURRENT
LIABILITIES

203,707

136,791

CREDITORS
Amounts falling due after more than one
year

7

1,560,258

490,258
NET LIABILITIES (1,356,551 ) (353,467 )

CAPITAL AND RESERVES
Called up share capital 8 1 1
Retained earnings (1,356,552 ) (353,468 )
SHAREHOLDERS' FUNDS (1,356,551 ) (353,467 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 12 September 2022 and were signed by:





Dr J A Loveridge - Director


INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022

1. STATUTORY INFORMATION

Invex Therapeutics Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2021 - 4 ) .

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2022

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 July 2021 2,083
Additions 2,591
At 30 June 2022 4,674
DEPRECIATION
At 1 July 2021 639
Charge for year 1,230
At 30 June 2022 1,869
NET BOOK VALUE
At 30 June 2022 2,805
At 30 June 2021 1,444

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/6/22 30/6/21
£    £   
Other debtors 314,751 110,027

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/6/22 30/6/21
£    £   
Trade creditors 67,228 -
Taxation and social security 1 -
Other creditors 137,638 1,735
204,867 1,735

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
30/6/22 30/6/21
£    £   
Amounts owed to group undertakings 1,560,258 490,258

8. CALLED UP SHARE CAPITAL


Allotted, issued and fully paid:
Number: Class: Nominal 30/6/22 30/6/21
value: £    £   
1 Ordinary share £1 1 1

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2022

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Benjamin Furness (Senior Statutory Auditor)
for and on behalf of Allens Accountants Limited